Conditions: Migraine
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 660
Healthy volunteers: no

Brief summary:
A study to assess the safety and efficacy of MK0974 for preventing migraines in patients with episodic migraine.

Detailed description:

Arms:
arm 1: Participants receive one telcagepant 140 mg tablet and one 280 mg telcagepant placebo, orally, twice daily for 12 weeks arm 2: Participants receive one telcagepant 280 mg tablet and one 140 mg telcagepant placebo, orally, twice daily for 12 weeks arm 3: Participants receive one 140 mg telcagepant placebo and one 280 mg telcagepant placebo, orally, twice daily for 12 weeks

Interventions: intervention 1: Telcagepant 140 mg intervention 2: Telcagepant 280 mg intervention 3: 140 mg telcagepant placebo intervention 4: 280 mg telcagepant placebo
Intervention descriptions: intervention 1: None intervention 2: None intervention 3: None intervention 4: None

Protocol document: